Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    Does Biological Therapy Protect against Severe COVID-19 MESHD?

    Authors: Ramon Mazzucchelli; Raquel Almodovar-Gonzalez; Natalia Crespi-Villarias; Elena Garcia-Zamora; Elia Perez-Fernandez; Javier Quiros-Donate; Monserrat Perez-Encinas; Patricia Sanmartin-Fenollera; Maria Velasco-Arribas; Pilar Lopez-Serrano; Jose lazaro Perez-Calle; Conrado Fernandez-Rodriguez; Jose Luis Lopez-Estebaranz; Pedro Zarco-Montejo

    doi:10.1101/2020.06.21.20136788 Date: 2020-06-24 Source: medRxiv

    Objective. To estimate COVID-19 MESHD infection incidence rate with severe affectation MESHD (requiring hospitalization) in patients with biological treatment due to rheumatoid arthritis MESHD ( RA MESHD), psoriatic arthritis MESHD ( PsA MESHD), spondyloarthritis MESHD ( SpA HGNC SpA MESHD), psoriasis MESHD ( Ps MESHD), and inflammatory bowel disease MESHD ( IBD MESHD) and compare it with incidence rate in the general population. Methods: Retrospective observational study based on information provided by two administrative databases. One of these two databases contains information on all patients seen in our hospital and diagnosed with COVID-19 MESHD infection between March 4th 2020 and April 26th 2020. The other database contains data from patients seen at Rheumatology, Dermatology and Digestive Departments in our hospital who are currently receiving biological therapy. We calculated the crude and age and sex adjusted incidence in both groups. To compare both groups we calculated the Incidence Rate Ratio. Results: There was a total of 2,182 patients with COVID-19 MESHD requiring hospitalization. Four patients out of a total of 797 patients receiving biological therapy had contracted COVID-19 MESHD and required hospital care. Crude incidence rate of COVID-19 MESHD requiring hospital care among the general population was 1.41%, and it was 0.50% among the group receiving biological therapy. Rates adjusted by age and sex in the biological group was 0.45% (CI95% 0.11-4.13). The IRR HGNC of the group receiving biological therapy compared to the general population was 0.39 (CI95% 0.14-1, p=0.049). Conclusion: Findings suggest that prior use of biological therapy does not associate with severe manifestations of COVID-19 MESHD, and it is likely to have a protective effect against them when compared to the general population.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.